Analysts See $-0.01 EPS for Neovasc Inc. (NVCN)

March 16, 2018 - By Clifton Ray

 Analysts See $ 0.01 EPS for Neovasc Inc. (NVCN)

Analysts expect Neovasc Inc. (NASDAQ:NVCN) to report $-0.01 EPS on March, 22.They anticipate $0.48 EPS change or 102.13 % from last quarter’s $0.47 EPS. After having $-0.06 EPS previously, Neovasc Inc.’s analysts see -83.33 % EPS growth. The stock decreased 16.97% or $0.0227 during the last trading session, reaching $0.1111. About 63.90 million shares traded or 574.67% up from the average. Neovasc Inc. (NASDAQ:NVCN) has declined 19.02% since March 16, 2017 and is downtrending. It has underperformed by 35.72% the S&P500.

Neovasc Inc. (NASDAQ:NVCN) Ratings Coverage

Among 3 analysts covering Neovasc (NASDAQ:NVCN), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Neovasc had 7 analyst reports since August 12, 2015 according to SRatingsIntel. The company was downgraded on Wednesday, August 26 by Zacks. The firm earned “Buy” rating on Wednesday, August 12 by Zacks. The stock of Neovasc Inc. (NASDAQ:NVCN) has “Neutral” rating given on Friday, May 20 by Ladenburg Thalmann. On Wednesday, October 7 the stock rating was initiated by JMP Securities with “Market Outperform”. The company was initiated on Thursday, December 10 by Ladenburg Thalmann. On Tuesday, August 25 the stock rating was maintained by Canaccord Genuity with “Buy”.

Neovasc Inc., a specialty medical device company, develops, makes, and markets cardiovascular devices worldwide. The company has market cap of $14.49 million. The Company’s products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. It has a 0.44 P/E ratio. The firm also provides Peripatch biological tissue products that are used as components in third-party medical products, such as transcatheter heart valves for industry partners and other customers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.